Clinical & Translational Oncology最新文献

{"title":"Diffuse large B-cell lymphoma: examining evolving patterns in mortality, incidence, and demographics.","authors":"Silpa Choday, Eric Tran, Miguel Gonzalez","doi":"10.1007/s12094-025-03859-4","DOIUrl":"https://doi.org/10.1007/s12094-025-03859-4","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, characterized by its aggressive nature and heterogeneity. This study analyzes recent trends in DLBCL including trends in hospitalization, inpatient mortality, and costs.</p><p><strong>Methods: </strong>Using the Nationwide Inpatient Sample (NIS) database from 2016 until 2020, a retrospective cohort study was performed to identify DLBCL hospitalization, discharges, and investigate outcomes. Trends were adjusted for age, sex, race, insurance type, mean household income, and hospital characteristics. Multivariable logistic regression has been used to analyze the data.</p><p><strong>Results: </strong>A total of 103,588,729 records were analyzed, identifying 47,425 cases with a diagnosis of DLBCL. From 2016 to 2020, hospitalizations have increased from 14,980 to 16,565. The mean age at diagnosis was 65 (P < 0.001). Males were slightly more affected than females (57.3 vs 42.6), with an increasing trend in males from 53.7% to 62.3% (P = 0.03). The highest prevalence was observed in the White population, followed by Hispanics and African Americans. Notably, the prevalence among Hispanics increased from 10 to 12%, while there is a decreasing trend in other demographics (P = 0.05). Medicare was the most common insurance, with increasing trends, followed by Medicaid and private insurance (P = 0.6). Inpatient mortality increased from 6.1 to 7.1 (2016 to 2018) and decreased to 6.1% (2018 to 2020) (P < 0.001). The mean length of the stay remained stable at 11.8 days. However, hospital charges increased from $176,131 to $212,324. Comorbidities such as obesity, hypertension, other associated lymphomas, peripheral vascular diseases, and diabetes showed an increasing trend (P < 0.05). Discharges to home and skilled nursing facility (SNF) decreased, while there was an increase in discharges to home with home health (HH) care and short-term care (P < 0.001).</p><p><strong>Conclusion: </strong>Risk factors for DLBCL include white male sex, with the mean age of 65 years. The incidence among the Hispanic population has been increasing over the years. There are disparities in incidence and survival among different ethnic/demographic groups that need to be addressed by identifying targeted interventions and equitable healthcare access.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.","authors":"Ignacio Peláez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, Emilio Esteban-González, Enrique Gallardo, Carlos Álvarez-Fernández, Pablo Álvarez Rodríguez, Urbano Anido-Herranz, Cristina Azpitarte Raposeiras, Ángel Maximino Castro-Iglesias, Ovidio Fernández Calvo, Natalia Fernández Núñez, Alicia Folgar-Torres, Carme García Lorenzo, Aránzazu González-Del-Alba, María José Méndez-Vidal, Aurea Molina Díaz, Ignacio Rodríguez Gómez, Sergio Vázquez-Estévez","doi":"10.1007/s12094-025-03850-z","DOIUrl":"10.1007/s12094-025-03850-z","url":null,"abstract":"<p><p>Prostate, bladder and kidney neoplasms are among the most prevalent genitourinary (GU) cancers worldwide. Significant therapeutic advancements in recent years have substantially improved patient outcomes. In response to this rapid progress, the Santiago de Compostela Health Research Institute (IDIS) has organized the annual 'Cambados Consensus Forum on Genitourinary Tumors' (Pontevedra, Spain) since 2018. This 2-day multidisciplinary meeting gathers Spanish medical oncologists, radiation oncologists, urologists, and hospital pharmacists to present and discuss the latest evidence in the field, merging from international congresses or journal publications. This review provides an overview of the most recent evidence regarding therapeutic advances in prostate cancer, renal cell carcinoma, and bladder cancer presented at the 2024 meeting (October), with a special focus on practice-changing innovations.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy.","authors":"Yuanliang Zhou, Jingchao Li, Yankang Li, Guangchuan Deng, Qi Wang, Hongyue Qin, Jianbin Li, Zhenxiang Li","doi":"10.1007/s12094-025-03867-4","DOIUrl":"https://doi.org/10.1007/s12094-025-03867-4","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burnout levels among radiation oncology residents in Spain: a cross-sectional survey.","authors":"Elías Gomis Sellés, María Mingarro de León, Ángel Montero, Meritxell Arenas","doi":"10.1007/s12094-025-03862-9","DOIUrl":"https://doi.org/10.1007/s12094-025-03862-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the prevalence and characteristics of burnout among Radiation Oncology residents in Spain, focusing on its associated risk factors and implications for residency training.</p><p><strong>Materials and methods: </strong>A cross-sectional online survey was conducted from June to September 2024, using the Maslach Burnout Inventory (MBI) to evaluate emotional exhaustion, depersonalization, and self-fulfillment. Residents from various Spanish regions completed an anonymous questionnaire covering workload and burnout.</p><p><strong>Results: </strong>Fifty residents, predominantly in their third (38%) and fourth (42%) years of training, participated. High emotional exhaustion was reported by 58%, while 54% exhibited elevated depersonalization. Self-fulfillment scores were low in 32%. Overall, 70% experienced at least one burnout symptom, with 12% meeting criteria for full-burnout syndrome. An inverse correlation between self-fulfillment and emotional exhaustion was observed (p = 0.007). Trends suggested higher burnout risk in senior residents (R3-R4) compared to juniors (R1-R2), though these differences were not statistically significant (OR = 1.682; p = 0.086).</p><p><strong>Conclusion: </strong>The findings reveal a high prevalence of at least one burnout symptom among Radiation Oncology residents in Spain, with emotional exhaustion and depersonalization notably elevated. However, full-burnout syndrome is not prevalent. These findings underscore the need for reforms in residency training programs, emphasizing workload management, well-being initiatives, and support for scientific and professional development.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"USP14 targets FABP5-mediated ferroptosis to promote proliferation and cisplatin resistance of HNSCC.","authors":"Jiaxin Qian, Zitong Zhao, Liying Ma, Wensheng Liu, Yongmei Song","doi":"10.1007/s12094-025-03857-6","DOIUrl":"https://doi.org/10.1007/s12094-025-03857-6","url":null,"abstract":"<p><strong>Background: </strong>Head and neck squamous cell carcinoma (HNSCC) ranks among the most lethal solid tumors in humans, with a five-year survival rate hovering around 50%. The limited understanding of its biological foundation has hindered the development of efficacious targeted therapeutics.</p><p><strong>Methods: </strong>TCGA database and immunohistochemistry were deployed to confirm the expression levels of ubiquitin specific protease 14 (USP14). CCK8 method was used to evaluate the influence of USP14 on cisplatin resistance. Further investigations into the role of USP14 were conducted through assessments of cell proliferation, colony formation, and Transwell assays. The impact of USP14 expression on ferroptosis was evaluated by measuring GSH/GSSG ratios, Fe²⁺ concentrations, and lipid peroxide levels. Co-IP was employed to verify the interaction between USP14 and FABP5.</p><p><strong>Results: </strong>Our analysis revealed that USP14 ranked among the most prominently upregulated deubiquitinases (DUBs) in tissue samples of HNSCC. Notably, aberrant USP14 expression was linked to tumorigenesis and the malignant evolution of HNSCC and further suggested a poor prognosis. In vitro experiment revealed that USP14 depletion markedly inhibited cell growth, cisplatin resistance, invasion and migration capabilities of HNSCC cells. Mechanically, USP14 inhibits FABP5 ubiquitination and degradation, thus positively modulating FABP5 expression. Subsequent analyses demonstrated that the loss of USP14 promoted ferroptosis in HNSCC cells. Finally, in vivo xenograft experiments confirmed that the USP14 small molecular antagonist IU1 could effectively attenuate cisplatin resistance in HNSCC.</p><p><strong>Conclusion: </strong>The results indicate that the USP14-FABP5 axis exerts oncogenic effects on HNSCC, providing a potential target for diagnosing and treating this type of malignancy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143383658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the benefits of immunotherapy in metastatic cervical cancer: an observational retrospective analysis.","authors":"Ana Isabel Martín-Quesada, Lina Pérez-Mendez, Natalia Dolores Pérez-Rodríguez","doi":"10.1007/s12094-025-03852-x","DOIUrl":"https://doi.org/10.1007/s12094-025-03852-x","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is the fourth most commonly diagnosed cancer and the fourth leading cause of cancer-related death in women globally. Recent advances in immunotherapy have demonstrated promising results. This study analyses the real-world impact of adding immunotherapy for patients with stage IV cervical carcinoma.</p><p><strong>Material and methods: </strong>This longitudinal retrospective observational study included patients with stage IV cervical carcinoma in the first metastatic setting treated between 2010 and 2023 at the University Hospital Nuestra Señora de Candelaria in Tenerife, Spain. To evaluate the primary objective, patients were divided into two groups depending on whether they had received immunotherapy with pembrolizumab or not. The primary endpoint was 12-month progression-free survival in patients receiving immunotherapy compared to those not receiving it.</p><p><strong>Results: </strong>A total of 56 patients were analyzed, of whom 31 were tested for PD-L1. Among those tested, 25 patients (84%) were PD-L1 positive, and 18 of them (72%) received immunotherapy. The objective response rate was significantly higher, being 94% in the group that received immunotherapy, compared to 32% in the group that did not (p < 0.001). At 12 months, the cumulative probability of progression-free survival was estimated at 94.4% for the immunotherapy group versus 59.7% in the non-immunotherapy group (p = 0.009), with a hazard ratio of 0.116 (CI_95%: 0015 - 0.883; p = 0.038). Immunotherapy alone or combined with bevacizumab showed similar progression-free survival probabilities. However, these outcomes were significantly different when compared to patients who received neither therapy (p < 0.001).</p><p><strong>Conclusions: </strong>Our findings confirm that immunotherapy significantly improves progression-free survival and objective response rates in metastatic cervical carcinoma, aligning with the results from the KEYNOTE-826 trial. The implementation of PD-L1 testing and the addition of immunotherapy whenever possible are challenges to be achieved in clinical practice.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SEOM-GEIS Spanish clinical guidelines for the management of soft‑tissue sarcomas (2024).","authors":"César Serrano, Marta Arregui, Irene Carrasco, Nadia Hindi, Javier Martínez-Trufero, Jerónimo Martínez-García, Áurea Molina, Ana Paisán, Raúl Sánchez, María Ángeles Sala","doi":"10.1007/s12094-024-03842-5","DOIUrl":"https://doi.org/10.1007/s12094-024-03842-5","url":null,"abstract":"<p><p>Soft-tissue sarcomas are rare, diverse malignant tumors of mesenchymal origin, requiring diagnosis and treatment by a specialized multidisciplinary team. Initial assessment includes radiology and biopsy, followed by wide surgical resection with clear margins for localized cases. Radiotherapy is recommended for large, deep, high-grade tumors or after incomplete resection, while perioperative chemotherapy may be considered for high-risk cases. In oligometastatic disease, combining local and systemic therapies is an option. Anthracycline-based chemotherapy is the first-line treatment in advanced disease, though other drugs show efficacy in certain subtypes. Given the limited options, enrolling in clinical trials is advised for patients needing further treatment.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive score for response to neoadjuvant chemotherapy in early-stage HR + /HER2- breast cancer.","authors":"João Queirós Coelho, Beatriz Lau, Rita Pichel, Laura Guerra, Hugo Miranda, Raquel Romão, Maria João Sousa, Fernando Gonçalves, Joana Simões, Sérgio Xavier Azevedo, António Araújo","doi":"10.1007/s12094-025-03856-7","DOIUrl":"https://doi.org/10.1007/s12094-025-03856-7","url":null,"abstract":"<p><strong>Introduction: </strong>Neoadjuvant chemotherapy (NACT) is a treatment option for early-stage hormone receptor-positive human epidermal growth factor receptor 2-negative (HR + /HER2-) breast cancer. Despite its use, pathological response rates in this subtype are often lower, and the impact of individual risk factors remains unclear. This study aimed to identify biomarkers and create a predictive score for NACT response.</p><p><strong>Methods: </strong>This retrospective, single-center study included patients with stage IIA-IIIC HR + /HER2- breast cancer treated with NACT and surgery (2019-2023). Multiple logistic regression analyzed associations between clinicopathological variables and pathologic response (partial/complete vs. absent) (p < 0.05). The best-performing model was used to develop a risk score.</p><p><strong>Results: </strong>The study included 101 patients. Significant predictors of pathological response included tumor grade (G2/3 vs. G1), menopausal status (pre- vs. post-menopausal), and intrinsic subtype (luminal B vs. A).</p><p><strong>Conclusions: </strong>A dynamic calculator was created incorporating grade, hormonal status, intrinsic subtype, and Ki-67. This tool provides real-time input, facilitating personalized therapeutic decision-making.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New evidence for miRNA testing in head and neck squamous cell cancer patients.","authors":"Blanca Pilar Galindo Torres, Raquel Alcaraz Ortega, Patricia Saiz López, María Isabel Adiego Leza, María Del Mar Moradillo Renuncio, Carlos García Girón, Miguel Víctor Grijalba Uche","doi":"10.1007/s12094-025-03854-9","DOIUrl":"https://doi.org/10.1007/s12094-025-03854-9","url":null,"abstract":"<p><strong>Purpose: </strong>Prognosis of HNSCC has not changed over the last decades. MicroRNAs mediate gene expression and participate in regulating cellular biological processes. Its aberrant expression is an important event in the development of several cancers, including head and neck squamous cell cancer. The aim of the study is to determine if circulating miRNAs are reliable diagnostic indicators and can be used to monitor head and neck cancer.</p><p><strong>Methods/patients: </strong>An observational, longitudinal, prospective, analytical study was conducted, with a case-control design, in which 37 head and neck squamous cell cancer patients at diagnosis were compared with 30 healthy patients. Blood samples were obtained and free miRNA expression levels of 17 miRNAs were determined by PCR-RT. Follow-up of HNSCC was carried out for one year with blood extractions at 7 days for surgical patients, and 1, 2, 6 and 12 months after finishing treatment for all patients.</p><p><strong>Results: </strong>Seventy-eight percent of the participants in HNSCC group and 57% among control group were men. Smokers and alcohol consumers exhibit increased susceptibility to HNSCC, and risk rises to 63.4% (R² = 0.634) when both factors are combined. HNSCC patients overexpressed miR-21-5p and miR-122, while miR-195-5p is downregulated. Elevated miR-21-5p levels correlates with tumour size and miR-374b-5p, with advanced stage (p = 0.005).</p><p><strong>Conclusion: </strong>Our findings suggest that the evaluation of certain miRNAs' expression levels in plasma can be used as potential markers for HNSCC diagnosis. Further assays with larger samples could be performed to validate data and establish a cut-off expression level for our proposed miRNAs.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.","authors":"Bilal Abu-Hussein, Amr Elrosasy, Haidy Samy, Ahmed Said Ali, Said Samir Alijla, Ahmad Naoras Bitar, Ibrahim Gamal","doi":"10.1007/s12094-025-03847-8","DOIUrl":"https://doi.org/10.1007/s12094-025-03847-8","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer remains a leading cause of morbidity and mortality among women worldwide. According to the recent statistics by World Health Organization (WHO), it is the leading cause of death from cancer in women worldwide and it is the most frequently diagnosed cancer. This meta-analysis aims to systematically evaluate the efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.</p><p><strong>Method: </strong>We searched five databases; PubMed, Scopus, Science Direct, Web of Science, and Medline Plus. We included six studies. The applicable outcomes for meta-analysis about efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.</p><p><strong>Results: </strong>Six RCTs included in our meta-analysis found that Esketamine group had a statistically significant lower VAS score after 4 h, after 6 h, after 24 h, after 48 h; (MD = -1.54; 95% CI [-1.65, -1.42], P < 0.00001), (MD = -0.55; 95% CI [-0.66, -0.45], P < 0.00001), (MD = -0.75; 95% CI [-0.84, -0.66], P < 0.00001,), (MD = -0.26; 95% CI [-0.48, -0.03], P = 0.03) P < 0.00001), respectively.</p><p><strong>Conclusion: </strong>We conclude that S-ketamine is valuable for reducing pain and safe in patients undergoing modified radical mastectomy.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}